| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/18/2002 | CA2581031A1 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
| 04/18/2002 | CA2462671A1 Normalization of defective t cell responsiveness through manipulation of thymic regeneration |
| 04/18/2002 | CA2462081A1 Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| 04/18/2002 | CA2459746A1 Pyrimidinone derivatives and their use in the treatment of atherosclerosis |
| 04/18/2002 | CA2427499A1 Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-.gamma. binding agents |
| 04/18/2002 | CA2425910A1 Treatment and prevention of gastrointestinal disease using antagonists or partial agonists of 5ht1a receptors |
| 04/18/2002 | CA2425828A1 Synthesis of epothilones and related analogs |
| 04/18/2002 | CA2425815A1 Treatment of t cell disorders |
| 04/18/2002 | CA2425779A1 Compositions that inhibit proliferation of cancer cells |
| 04/18/2002 | CA2425773A1 Compositions for improving lipid metabolism |
| 04/18/2002 | CA2425771A1 Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 04/18/2002 | CA2425678A1 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425674A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425672A1 Use of substituted imidazo[1,2-a]-pyridin-,pyrimidin-and -pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting nos |
| 04/18/2002 | CA2425666A1 Substituted 3.4-dihydro-pyrido[1,2-a]pyrimidines |
| 04/18/2002 | CA2425655A1 Drugs for diabetes |
| 04/18/2002 | CA2425650A1 Methods for the treatment of a traumatic central nervous system injury |
| 04/18/2002 | CA2425649A1 Nitroderivatives as drugs for diseases having an inflammatory basis |
| 04/18/2002 | CA2425632A1 Agents for the treatment of viral infections |
| 04/18/2002 | CA2425610A1 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 04/18/2002 | CA2425593A1 Uridine therapy for patients with elevated purine levels |
| 04/18/2002 | CA2425581A1 Modulation of ligand binding/enzymatic activity of alpha beta proteins |
| 04/18/2002 | CA2425540A1 Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]piperazine.hydrochloride |
| 04/18/2002 | CA2425508A1 Targeted therapeutic agents |
| 04/18/2002 | CA2425416A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and methods for preparing same |
| 04/18/2002 | CA2425359A1 Dioxolane analogs for improved inter-cellular delivery |
| 04/18/2002 | CA2425356A1 Hedgehog antagonists, methods and uses related thereto |
| 04/18/2002 | CA2425259A1 Modulation of ccr4 function |
| 04/18/2002 | CA2425187A1 Detection of neurodegenerative disorders |
| 04/18/2002 | CA2425121A1 Ether compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425035A1 Medicinal aerosol formulations |
| 04/18/2002 | CA2424987A1 Methods of agonizing and antagonizing fabk |
| 04/18/2002 | CA2424971A1 Topoisomerase inhibitors |
| 04/18/2002 | CA2424951A1 Beta-amino acid derivatives as integrin receptor antagonists |
| 04/18/2002 | CA2424823A1 Treatment of cancers by aplidine in conjunction with a myoprotector |
| 04/18/2002 | CA2424812A1 Benzodiazepine derivatives as inhibitors of gamma secretase |
| 04/18/2002 | CA2424802A1 Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same |
| 04/18/2002 | CA2424785A1 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 04/18/2002 | CA2424587A1 A nutritional dietary system, formulation, kit and method for use in preparing an individual for a predetermined activity |
| 04/18/2002 | CA2424585A1 Remedies for retinal nerve diseases containing 1,2-ethanediol derivatives or salts thereof |
| 04/18/2002 | CA2424444A1 Topical antibiotic composition for treatment of eye infection |
| 04/18/2002 | CA2424438A1 Anhydro sugar derivatives of indolocarbazoles |
| 04/18/2002 | CA2424317A1 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products |
| 04/18/2002 | CA2424299A1 Combination therapy for the treatment of estrogen-sensitive disease |
| 04/18/2002 | CA2424292A1 Tricyclic compounds and uses thereof |
| 04/18/2002 | CA2424107A1 Sulfonylguanidines |
| 04/18/2002 | CA2424055A1 Medication delivery devices |
| 04/18/2002 | CA2423935A1 Substituted c-cyclohexylmethylamine derivatives |
| 04/18/2002 | CA2423515A1 Pyrazole derivatives for the treatment of viral diseases |
| 04/18/2002 | CA2423316A1 A method of determining the initial dose of vitamin d compounds |
| 04/18/2002 | CA2422744A1 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
| 04/18/2002 | CA2394084A1 Inhibitors of protein kinases |
| 04/17/2002 | EP1197550A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 04/17/2002 | EP1197491A1 Thioxanthenone antitumor agents |
| 04/17/2002 | EP1197488A1 (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use |
| 04/17/2002 | EP1197485A1 Cyclobuten-dione derivatives for use in the treatment of artherosclerosis |
| 04/17/2002 | EP1197484A2 1H-Indole-3-glyoxylamide sPLA2 inhibitors |
| 04/17/2002 | EP1197483A2 Process for the catalytic reduction of alkyne compounds |
| 04/17/2002 | EP1197228A1 Medicinal compositions for treating colorectal cancer |
| 04/17/2002 | EP1197227A1 Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method |
| 04/17/2002 | EP1197226A1 Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| 04/17/2002 | EP1197223A1 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy |
| 04/17/2002 | EP1197222A2 A stabilized pharmaceutical formulation comprising growth hormone and histidine |
| 04/17/2002 | EP1197221A1 Preparations stabilized over long time |
| 04/17/2002 | EP1197220A2 Therapeutic methods and compositions based on delta proteins and nucleic acids |
| 04/17/2002 | EP1197218A1 Algae protein polysaccharide extraction and use thereof |
| 04/17/2002 | EP1197217A1 Use of sodium nitroprussiate in obstetrics and gynaecology |
| 04/17/2002 | EP1197216A1 Pharmaceutical or cosmetic composition containing polyglucan ether derivatives |
| 04/17/2002 | EP1197215A2 Anthelmintic compositions |
| 04/17/2002 | EP1197214A1 Medicinal compositions for preventing or treating diarrhea |
| 04/17/2002 | EP1197213A2 Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis |
| 04/17/2002 | EP1197212A1 Adhesive preparation for percutaneous absorption |
| 04/17/2002 | EP1197211A1 Preventive and therapeutic agents for cancer |
| 04/17/2002 | EP1197210A1 Agents inhibiting chronic rejection reactions after organ transplantation |
| 04/17/2002 | EP1197207A2 Stable compositions for parenteral administration |
| 04/17/2002 | EP1196782A1 Catalytic anti-factor viii allo-antibodies |
| 04/17/2002 | EP1196635A2 Cell death related drug targets in yeast and fungi |
| 04/17/2002 | EP1196616A2 Replication-competent anti-cancer vectors |
| 04/17/2002 | EP1196609A2 Catalytically active recombinant memapsin and methods of use thereof |
| 04/17/2002 | EP1196587A2 Antigenic meningococcal peptides |
| 04/17/2002 | EP1196584A1 Tetanus toxin polypeptides |
| 04/17/2002 | EP1196575A2 Gtp-binding protein associated factors |
| 04/17/2002 | EP1196570A2 Human polypeptides and methods for the use thereof |
| 04/17/2002 | EP1196565A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 04/17/2002 | EP1196562A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 04/17/2002 | EP1196560A1 Neurotrophic factor receptor gfr-alpha-4 |
| 04/17/2002 | EP1196559A1 Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| 04/17/2002 | EP1196441A1 Keratinocyte growth factor-2 |
| 04/17/2002 | EP1196436A2 Peptide boronic acid inhibitors of hepatitis c virus protease |
| 04/17/2002 | EP1196431A1 A substantially crystalline form of melagatran |
| 04/17/2002 | EP1196428A1 11$g(b)-ARYL-17,17-SPIROTHIOLANE-SUBSTITUTED STEROIDS |
| 04/17/2002 | EP1196427A2 Novel c-19-halogen-substituted steroids of the androst-9(11)-ene-series, methods for the production and use thereof |
| 04/17/2002 | EP1196419A1 Potassium channel blocking agents |
| 04/17/2002 | EP1196418A1 METHOD FOR PREPARING SUBSTITUTED 1,4]DIAZEPINO 6,7,1- i hi /i ]INDOL-4-ONES |
| 04/17/2002 | EP1196417A1 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION |
| 04/17/2002 | EP1196416A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 04/17/2002 | EP1196414A1 Prodrugs of carbamate inhibitors of impdh |
| 04/17/2002 | EP1196412A1 Nitrogen containing heterobicycles as factor xa inhibitors |
| 04/17/2002 | EP1196411A1 Bradykinin b1 receptor antagonists |
| 04/17/2002 | EP1196410A1 Respiratory syncytial virus replication inhibitors |